Nature

HIV-1 Reverse Transcriptase Inhibitors and Drug Resistance

HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...
HealthDay on MSN

Switching from HIV protease inhibitors to integrase strand transfer inhibitors tied to diabetes risk

Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV, according to a study published online March 27 in The Lancet ...
Medscape

Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children

Clin Drug Invest. 2007;27(8):509-531. Antiretroviral drugs (ARVs) can be divided into four different classes according to their modes of action: nucleoside or nucleotide reverse transcriptase ...
Medscape

Etravirine: A Novel Nonnucleoside Reverse Transcriptase Inhibitor for Managing Human Immunodeficiency Virus Infection

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.
Monthly Prescribing Reference

Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia. HealthDay News — Exposure to nucleoside reverse transcriptase inhibitors ...

Switching to integrase inhibitors from protease inhibitors is associated with new diabetes risk in people with HIV

Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to the National Institutes of Health. Antiretroviral therapies that treat HIV ...
BioWorld

Reverse transcriptase inhibitors can prevent cancer drug resistance

Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The ...
Monthly Prescribing Reference

Reverse Transcriptase Inhibitor Fast Tracked for Progressive Supranuclear Palsy

After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...
Business Insider

ROME Therapeutics Debuts First Preclinical Data of its LINE-1 Reverse Transcriptase (RT) Inhibitors in Neurodegenerative Diseases at 3rd Annual Dark Genome Symposium

BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- ROME Therapeutics, a biotechnology company illuminating the intersection of the dark genome and innate immunity to develop breakthrough medicines for ...
Aidsmap

Doravirine/islatravir non-inferior to Biktarvy as first-line treatment

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
Nature

HIV-1 Reverse Transcriptase Inhibitors

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...